NBIX Stock Dips 12% in a Month: Time to Buy, Hold or Sell?

Shares of Neurocrine Biosciences NBIX have lost about 12% over the past month, despite encouraging second-quarter 2026 earnings and an upgraded outlook reported toward the end of last month.

The recent weakness appears to be driven largely by growing safety concerns surrounding Vykat XR, the recently approved Prader-Willi syndrome (PWS) treatment NBIX acquired from Soleno Therapeutics earlier this year.

While near-term pressure reflects investor concerns about Vykat XR’s outlook, the company’s investment case extends beyond a single product. Investors should also consider the strength of Neurocrine’s existing portfolio, its growth opportunities, financial performance and the potential impact of concerns surrounding Vykat XR on its broader outlook.

Let’s explore the company’s fundamentals to better understand how to play the stock amid the recent decline.

Ingrezza Remains Key Value Driver for NBIX

The blockbuster VMAT2 inhibitor remains Neurocrine’s primary revenue driver and a key pillar of its growth story. Momentum has remained strong in 2026, with first-half sales rising 17% year over year to $1.4 billion, supported by record new prescriptions and double-digit volume growth. The strong performance prompted management to raise its Ingrezza sales guidance for full-year 2026 to $2.83-$2.88 billion from $2.7-$2.8 billion. The new range suggests roughly 13% year-over-year growth at the midpoint.

Ingrezza is approved for two indications — tardive dyskinesia (TD) and chorea associated with Huntington's disease (HD) — both of which offer substantial room for further growth. Neurocrine Biosciences estimates that TD affects approximately 800,000 people in the United States, while chorea affects the vast majority of the roughly 40,000 Americans living with HD. This sizable addressable market provides the company with meaningful opportunities to expand Ingrezza adoption over the longer term.

Crenessity Diversifies NBIX’s Growth Engine

Neurocrine is making meaningful progress in diversifying beyond Ingrezza, with Crenessity emerging as an important second growth driver. Launched in December 2024 for patients aged four years and older with classic congenital adrenal hyperplasia (CAH), Crenessity generated $337 million in first-half 2026 sales, up roughly 400% year over year and surpassing $301 million generated in 2025. With only about 15% of the diagnosed classic CAH population estimated to have received Crenessity, the drug still has substantial room to expand its penetration.

Neurocrine has not yet provided sales guidance for Crenessity, as the launch remains relatively early and the company continues to learn more about the market and the drug’s growth trajectory. The expanding prescriber base, steady new patient additions and strong persistence point to continued growth potential, supporting the CAH drug’s role as an increasingly important contributor to Neurocrine’s diversified revenue base.

Vykat XR Broadens NBIX’s Portfolio, But Faces Near-Term Headwinds

Vykat XR adds another potential growth opportunity to Neurocrine’s portfolio, but its near-term outlook remains less certain. Since the acquisition of Soleno Therapeutics closed in mid-May 2026, Vykat XR contributed $54 million to reported second-quarter sales, while pro forma sales for the full quarter totaled $94 million.

Management expects discontinuations stemming from the initial launch bolus to largely work through in the third quarter of 2026, with sequential sales growth anticipated beginning in the fourth quarter. The long-term discontinuation rate is expected to settle at around 25-30%.

However, post-marketing serious adverse events have been reported to the FDA, although such reports do not establish that Vykat XR caused the events. Neurocrine has acknowledged that safety concerns could affect market acceptance, trigger regulatory scrutiny, or lead to higher treatment discontinuation rates. As the company continues to educate healthcare providers and monitor patient persistence, Vykat XR’s safety profile, retention trends, and prescriber adoption will remain key factors for investors to watch.

Competitive Pressure in Targeted Markets

Teva Pharmaceuticals TEVA remains a key competitor to Neurocrine in the VMAT2 market, with Austedo and Austedo XR competing with Ingrezza across both approved indications. The competitive threat could increase as Austedo and Austedo XR enter the Medicare Drug Price Negotiation Program in 2027. The Centers for Medicare & Medicaid Services (CMS) has set negotiated prices below pre-negotiation levels, which could make Teva’s therapies more price-competitive for Medicare patients and potentially drive greater uptake, putting additional pressure on Ingrezza’s market share and pricing.

Competition could also increase as Neurocrine advances its neurology/psychiatry pipeline, including candidates for schizophrenia and major depressive disorder, where newer therapies such as Bristol Myers Squibb’s BMY Cobenfy are gaining traction. Successful competing treatments could limit the commercial opportunity for Neurocrine’s future launches.

NBIX’s Stock Performance, Valuation & Estimates

Despite the recent weakness, shares of Neurocrine Biosciences have outperformed both the industry and the broader sector on a year-to-date basis. However, the stock has lagged the S&P 500 index during the same period, as seen in the chart below.

NBIX Stock Performance

Image Source: Zacks Investment Research

The company is currently trading at a premium to the industry. Based on the price-to-sales (P/S) ratio, the stock trades at 3.63 times forward 12-month sales, above the industry average of 2.02 times.

Image Source: Zacks Investment Research

Estimate revisions for Neurocrine Biosciences’ 2026 and 2027 EPS have risen over the past 30 days.

Image Source: Zacks Investment Research

How to Play NBIX Stock?

Neurocrine’s strong commercial execution and diversified pipeline support a favorable long-term growth outlook. Ingrezza continues to deliver double-digit growth, while Crenessity is rapidly expanding and Vykat XR could become an additional growth driver as the launch matures. The company also has a rich pipeline, with about 10 clinical readouts expected in 2027, including phase III data for osavampator in MDD and direclidine in schizophrenia.

However, it may be too early to take an aggressive position in the stock. Investors still need greater visibility into Vykat XR’s safety profile, patient retention and commercial trajectory, while longer-term pricing and competitive pressures on Ingrezza remain considerations. Pipeline execution risk also remains a concern.

Given the mixed risk-reward profile, investors may want to adopt a wait-and-watch approach toward this Zacks Rank #3 (Hold) company for now. As Vykat XR’s trajectory becomes clearer and Neurocrine reports key pipeline data, investors could gain better visibility into the company’s longer-term growth prospects and reassess the stock’s investment case.

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research